Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Teva Pharmaceutical Industries rose $0.40 (1.0%) to $39.56 on light volume. Throughout the day, 2,281,757 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3,608,200 shares. The stock ranged in a price between $38.99-$39.56 after having opened the day at $39.10 as compared to the previous trading day's close of $39.16. Other companies within the Drugs industry that increased today were: Rockwell Medical ( RMTI), up 19.5%, Prothena Corporation ( PRTA), up 15.9%, XOMA ( XOMA), up 15.3% and Alnylam Pharmaceuticals ( ALNY), up 15.0%.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.0 billion and is part of the health care sector. Shares are up 3.8% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 34.6%, Synthetic Biologics ( SYN), down 12.3%, Neostem ( NBS), down 7.8% and pSivida ( PSDV), down 7.7% , were all laggards within the drugs industry with Theravance ( THRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.